Jump to navigation Jump to search

WikiDoc Resources for Antianginal


Most recent articles on Antianginal

Most cited articles on Antianginal

Review articles on Antianginal

Articles on Antianginal in N Eng J Med, Lancet, BMJ


Powerpoint slides on Antianginal

Images of Antianginal

Photos of Antianginal

Podcasts & MP3s on Antianginal

Videos on Antianginal

Evidence Based Medicine

Cochrane Collaboration on Antianginal

Bandolier on Antianginal

TRIP on Antianginal

Clinical Trials

Ongoing Trials on Antianginal at Clinical

Trial results on Antianginal

Clinical Trials on Antianginal at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Antianginal

NICE Guidance on Antianginal


FDA on Antianginal

CDC on Antianginal


Books on Antianginal


Antianginal in the news

Be alerted to news on Antianginal

News trends on Antianginal


Blogs on Antianginal


Definitions of Antianginal

Patient Resources / Community

Patient resources on Antianginal

Discussion groups on Antianginal

Patient Handouts on Antianginal

Directions to Hospitals Treating Antianginal

Risk calculators and risk factors for Antianginal

Healthcare Provider Resources

Symptoms of Antianginal

Causes & Risk Factors for Antianginal

Diagnostic studies for Antianginal

Treatment of Antianginal

Continuing Medical Education (CME)

CME Programs on Antianginal


Antianginal en Espanol

Antianginal en Francais


Antianginal in the Marketplace

Patents on Antianginal

Experimental / Informatics

List of terms related to Antianginal


An antianginal is any drug used in the treatment of angina pectoris, a symptom of ischaemic heart disease.

Drugs used are nitrates such as nitroglycerin (glyceryl trinitrate) or pentaerythritol tetranitrate; beta blockers, either cardioselectives such as acebutolol or metoprolol, or non-cardioselectives such as oxprenolol or sotalol; or calcium channel blockers, either Class I agents (e.g., verapamil), Class II agents (e.g., amlodipine, nifedipine), or the Class III agent diltiazem.

Nitrates cause vasodilation of the venous capacitance vessels by simulating the endothelium-derived relaxing factor (EDRF). Used to relieve both exertional and vasospastic angina by allowing venous pooling, reducing the pressure in the ventricles and so reducing wall tension and oxygen requirements in the heart. Short-acting nitrates are used to abort angina attacks that have occurred, while longer-acting nitrates are used in the prophylactic management of the condition.

Beta blockers are used in the prophylaxis of exertional angina by reducing the work the heart is allowed to perform below the level that would provoke an angina attack. They cannot be used in vasospastic angina and can precipitate heart failure.

Calcium ion (Ca++) antagonists (Calcium channel blockers) are used in the treatment of both exertional and vasospastic angina. In vitro, they dilate the coronary and peripheral arteries and have negative inotropic and chronotropic effects - decreasing afterload, improving myocardial efficiency, reducing heart rate and improving coronary blood flow. In vivo, the vasodilation and hypotension trigger the baroreceptor reflex. Therefore the net effect is the interplay of direct and reflex actions. Class I antiarrhythmic agents have the most potent negative inotropic effect and may cause heart failure; Class II agents do not depress conduction or contractility; the Class III agent has negligible inotropic effect and causes almost no reflex tachycardia.

Template:Major Drug Groups

Template:WH Template:WS